Close Menu

SEATTLE (GenomeWeb) – A new analysis from Invitae suggests a significant proportion of informative, pathogenic cancer risk variants may be missed by focusing germline genetic tests in cancer patients on relatively few genes with potential ties to an individual's cancer type.

Invitae's Edward Esplin outlined results from the study during a session on cancer risk assessment and management at the American College of Medical Genetics and Genomics annual meeting here on Friday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.